Patients in the #EU with rare disease #thymidinekinase2deficiency (TK2d) have their first approved therapy, #UCB's #Kygevi, after the #EuropeanCommission cleared the drug "under exceptional circumstances."

pharmaphorum.com/news/ucb-bri...